Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in Refractory Solid Tumors with PIK3CA/PTEN Alterations
NCT02449538Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Feb 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in solid tumor, sponsored by Samsung Medical Center. Started Feb 2015; status: completed.
02
Drugs
everolimus
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02449538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02449538.